Immunoassays are commonly used as a first-line screening method for detecting drugs of abuse. They lack the sensitivity, however, to detect designer drugs. The technique also requires additional confirmation, which slows the analytical process.

This is where mass spectrometry (MS) comes in. By switching to MS for your drug analysis, your lab can expect analyte-specific results and accurate quantification with higher sensitivity and resolving power than immunoassay.

Download this technical note to access a method, aligned with the NSC-ADID recommendations, to rapidly identify drugs in blood samples on the SCIEX X500R QTOF.

Relates to RUO-MKT-18-8413-A

© 2019 DH Tech. Dev. Pte. Ltd.
500 Old Connecticut Path, Framingham, MA 01701, US

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd., or their respective owners, in the United States and/or certain other countries.

AB Sciex^™ is being used under license.

Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of LCGC, an MJH Life Sciences™ brand. You are on the mailing list as %%emailaddress%%.